BDX - Becton Dickinson
227.68
| Index: | S&P 500 | P/E: | 38.33 | EPS (ttm): | 5.94 | Insider Own: | 0.17% | Shs Outstand: | 290.01M | Perf Week: | 0.94% |
| Market Cap: | 67.16B | Forward P/E: | 14.49 | EPS next Y: | 15.71 | Insider Trans: | -2.04% | Shs Float: | 289.52M | Perf Month: | 2.38% |
| Income(ttm): | 1.73B | PEG: | 4.26 | EPS next Q: | 2.99 | Inst Own: | 90.31% | Short Float: | 0.65% | Perf Quarter: | -3.00% |
| Revenue(ttm): | 20.18B | P/S: | 3.33 | EPS this Y: | 9.69% | Inst Trans: | 0.91% | Short Ratio: | 1.14 | Perf Half Y: | -3.49% |
| Book/sh: | 89.55 | P/B: | 2.54 | EPS next Y: | 9.00% | ROA: | 3.14% | Short Interest: | 1.90M | Perf Year: | -5.06% |
| Cash/sh: | 7.80 | P/C: | 29.19 | EPS next 5Y: | 9.00% | ROE: | 6.68% | 52W Range: | 218.75 - 249.89 | Perf YTD: | -6.62% |
| Dividend Est.: | 3.88 (1.70%) | P/FCF: | 21.86 | EPS past 5Y: | 8.27% | ROI: | 3.88% | 52W High: | -8.89% | Beta: | 0.40 |
| Dividend TTM: | 3.89 (1.71%) | Quick Ratio: | 0.74 | Sales past 5Y: | 4.72% | Gross Margin: | 45.36% | 52W Low: | 4.08% | ATR (14): | 4.53 |
| Dividend Ex-Date: | Dec 09, 2024 | Current Ratio: | 1.17 | EPS Y/Y TTM: | 19.34% | Oper. Margin: | 14.29% | RSI (14): | 53.62 | Volatility: | 2.45% 1.88% |
| Employees: | 74000 | Debt/Eq: | 0.81 | Sales Y/Y TTM: | 4.16% | Profit Margin: | 8.55% | Recom: | 1.44 | Target Price: | 275.23 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 0.72 | EPS Q/Q: | 292.60% | Payout: | 64.86% | Rel Volume: | 1.86 | Prev Close: | 223.83 |
| Sales Surprise: | 1.06% | EPS Surprise: | 1.12% | Sales Q/Q: | 6.88% | Earnings: | Nov 07 BMO | Avg Volume: | 1.66M | Price: | 227.68 |
| SMA20: | 1.82% | SMA50: | -1.08% | SMA200: | -2.84% | Undervalued: 20.88% | Volume: | 3,083,279 | Change: | 1.72% | |
Graham Classic formula value: 141.35
(P/E=8 * 1g) Min value: 90.68
(current P/E * 2g) Max value: 300.46
Average value: 177.5
Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.